Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: European Comission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
  • Location: Europe
eu mascara


EU-MASCARA logoThe Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA) consortium aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analyzing a panel of biomarkers. EU-MASCARA aims to validate biomarkers that have been proposed to be associated with cardiovascular disease and risk across different disease entities and also in independent general population samples. The most robust biomarkers will be implemented in novel biochip-based assays for clinical use.


The Markers for Sub-Clinical Cardiovascular Risk Assessment (EU-MASCARA) consortium aims to examine genetic, proteomic, and metabolomic markers together with markers of inflammation, oxidative stress, and cardiac remodeling to study their incremental diagnostic and predictive value over and above existing diagnostic and predictive algorithms. For this purpose, a large number of cohorts from different European regions, both patient and population cohorts that have been accurately assessed for cardiovascular phenotypes, are readily available to the consortium. Access to clinical samples and to standardized cardiovascular phenotypes will be granted by a strong clinical platform as one of the key work packages of EU-MASCARA. Both cross-sectional and prospective analyses will be performed in hopes of developing improved risk prediction scores.

Consortium History

Start date: Dec. 1, 2011
End date: Nov. 30, 2015

Structure & Governance

The consortium is heavily supported by contributions of SMEs in key areas of the proposed research: biomarker testing, data handling and analysis, assay development, and project management. EU-MASCARA is further characterized by a strong integrative approach both within and across work packages, with results from one task informing strategies of research in other tasks. With a dedicated bioinformatics and health economic platform, the most robust biomarkers will be selected and analyzed for their benefit in clinical practice.


Funded by EU FP7.

Over 80 peer-reviewed published papers, most recently “Heritability and other determinants of left ventricular diastolic function in the family-based population study.”


Points of Contact

Kite Innovation (Europe) Ltd
Studio 8
The Media Centre
Northumberland Street

Sponsors & Partners

University of Glasgow

Emergentec Biodevelopment GmbH

Kite Innovation (Europe) Limited

La Fundacion para la investigacion del Hospital Clinico de la Comunidad Valenciana

ACS Biomarker BV

Istituto Auxologico Italiano

Randox Clinics Limited

Maastricht University

Fundacian Para la Investigacion Medica Aplicada FIMA

Mosaiques Diagnostics GmbH

Medizinische Universitat Graz

Medizinische Hochschule Hannover

Universita degli Studi di Milano – Bicocca

Katholieke Universiteit Leuven

Charite – Universitatsmedizin Berlin

Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.